HK Stock Market Move | SIMCERE PHARMA(02096) has risen nearly 9% again. Major banks such as UBS have given it a "buy" rating. The company's performance has achieved significant growth.

SIMCERE PHARMA (02096) surged nearly 9%, rising 7.92% to HK$10.63 as of press time, with a turnover of HK$150.386 million. In recent news, Stanford University School of Medicine has reached a cooperation research agreement with SIMCERE PHARMA to develop innovative therapies for patients with idiopathic pulmonary fibrosis (IPF). According to the agreement, SIMCERE PHARMA will fund exploratory research on this first-in-class molecule, and upon successful completion, will be granted the rights and 100% global ownership of the product. It is worth noting that UBS has reiterated a "buy" rating for SIMCERE PHARMA with a target price of HK$16.30. At the same time, Wall Street analysts generally give SIMCERE PHARMA a unanimous "strong buy" rating, with an average target price of HK$17.77. Based on the latest quarterly results up to December 31, 2025, SIMCERE PHARMA achieved revenue of HK$4.15 billion and a net profit of HK$740.4 million for the quarter. In comparison, for the same period last year, the company's revenue was HK$3.52 billion and the net profit was HK$276.57 million.